HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $568
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $500 to $568.
HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $500 to $568.